HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.

AbstractBACKGROUND AND PURPOSE:
We aimed to evaluate a modified tissue-type plasminogen activator, SUN9216, and the combination of SUN9216 and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
METHODS:
Under anesthesia, the left middle cerebral artery was observed under an operation microscope without cutting the dura mater via a subtemporal craniotomy. Photoillumination (wave length, 540 nm) was applied to the middle cerebral artery, and then rose bengal (20 mg/kg) was administered intravenously. The reopening of the middle cerebral artery by SUN9216, injected 30 minutes after middle cerebral artery occlusion, was observed under an operation microscope for a 60-minute observation period. Twenty-four hours after the operation, sections of the cerebrum were stained with triphenyltetrazolium chloride, and the area of cerebral infarction was analyzed by a computer.
RESULTS:
The combination of SUN9216 and vapiprost caused reopening of the middle cerebral artery in 58.8% of the rats, which was a greater percentage than that achieved with SUN9216 alone (31.6%). In contrast, saline did not cause reopening of the middle cerebral artery during the 60-minute observation period. The area of cerebral infarction in rats reperfused with SUN9216 was significantly reduced compared with that in the control group. The infarction area in rats treated with the combination of SUN9216 and vapiprost was reduced compared with that in rats treated with SUN9216 alone; this was the case whether or not the occlusion was reperfused. There was a significant correlation between the time of reopening of the middle cerebral artery and area of cerebral infarction.
CONCLUSIONS:
A single injection of SUN9216 was effective in recanalizing the vessel and reducing the area of cerebral infarction.
AuthorsK Umemura, K Wada, T Uematsu, M Nakashima
JournalStroke (Stroke) Vol. 24 Issue 7 Pg. 1077-81; discussion 1081-2 (Jul 1993) ISSN: 0039-2499 [Print] United States
PMID8322383 (Publication Type: Journal Article)
Chemical References
  • Biphenyl Compounds
  • Drug Combinations
  • Heptanoic Acids
  • Receptors, Thromboxane
  • lanoteplase
  • Plasminogen Activators
  • Tissue Plasminogen Activator
  • vapiprost
Topics
  • Animals
  • Biphenyl Compounds (pharmacology)
  • Cerebral Infarction (drug therapy, pathology)
  • Disease Models, Animal
  • Drug Combinations
  • Drug Evaluation, Preclinical
  • Heptanoic Acids (pharmacology)
  • Intracranial Embolism and Thrombosis (drug therapy, pathology)
  • Male
  • Plasminogen Activators (pharmacology)
  • Rats
  • Rats, Wistar
  • Receptors, Thromboxane (antagonists & inhibitors)
  • Time Factors
  • Tissue Plasminogen Activator (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: